ReachRxResearch
Home
Research
Sign Up
Study limitation
Back to Research Hub
  1. Home
  2. Research Hub
  3. Study limitation

Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis

Study limitation reported by the research below: “Composite kidney-disease progression was a secondary endpoint; the trial's primary endpoint (urinary protein-to-creatinine ratio reduction) was reported in a prior publication, so this paper represents final but not first efficacy reporting.”

Papers